As of May 2025, DMX-200 (also known by its proposed brand name QYTOVRA®) is not prescribed for hepatitis in Japan. The drug is currently undergoing Phase 3 clinical trials for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disease, and has not received approval for any indication, including hepatitis, in Japan.In January 2025, Dimerix Limited entered into an exclusive development and license agreement with FUSO Pharmaceutical Industries for the development and commercialization of DMX-200 in Japan specifically for FSGS. The Japanese Pharmaceutical and Medical Devices Agency (PMDA) has approved the ACTION3 Phase 3 clinical trial for DMX-200 in FSGS, with patient recruitment underway.It’s important to note that DMX-200 is not being developed or tested for hepatitis treatment in Japan. In fact, individuals with active hepatitis B or C infections are excluded from participating in the ongoing clinical trials for DMX-200.Therefore, DMX-200 is not prescribed for hepatitis in Japan. If you are seeking treatment options for hepatitis, it is advisable to consult with a healthcare professional for guidance on approved therapies.
DXB Price at posting:
57.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)